Maxim Group reaffirmed their buy rating on shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) in a research report released on Wednesday morning, MarketBeat reports. They currently have a $7.00 price target on the stock, down from their previous price target of $11.00.
A number of other equities research analysts also recently weighed in on the stock. Benchmark started coverage on shares of Sonoma Pharmaceuticals in a research report on Thursday, December 28th. They issued a speculative buy rating and a $10.00 price target for the company. Zacks Investment Research downgraded shares of Sonoma Pharmaceuticals from a buy rating to a hold rating in a research report on Thursday, January 11th.
Shares of Sonoma Pharmaceuticals (SNOA) opened at $4.40 on Wednesday. The company has a current ratio of 4.62, a quick ratio of 4.56 and a debt-to-equity ratio of 0.01. Sonoma Pharmaceuticals has a 1 year low of $4.16 and a 1 year high of $8.25.
A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Deutsche Bank AG acquired a new stake in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 25,141 shares of the company’s stock, valued at approximately $137,000. Deutsche Bank AG owned approximately 0.54% of Sonoma Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.00% of the company’s stock.
WARNING: “Sonoma Pharmaceuticals (SNOA) Earns “Buy” Rating from Maxim Group” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/02/17/sonoma-pharmaceuticals-snoa-earns-buy-rating-from-maxim-group.html.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.